23 Mar 2015 07:00
Press Release | 23 March 2015 |
Avacta Group plc
("Avacta" or the "Group")
Issue of Equity
Avacta Group plc (AIM: AVCT), the global provider of proprietary diagnostic tools, consumables and reagents for human and animal healthcare, today announces that 150,000 Ordinary Shares of 0.1p ("new Ordinary Shares") have been issued by the Company pursuant to the exercise of share options by employees.
Application will be made for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 26 March 2015.
The total number of Ordinary Shares in issue following the above issue will be 4,975,299,550 each with voting rights. No Ordinary Shares are held in Treasury.
The above figure of 4,975,299,550 shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FSA's Disclosure and Transparency Rules.
- Ends -
Enquiries:
Avacta Group plc | Tel: +44 (0) 844 414 0452 | |
Alastair Smith, Chief Executive Officer | www.avacta.com | |
Tim Sykes, Chief Financial Officer | ||
Numis Securities Limited | Tel: +44 (0) 207 260 1000 | |
Michael Meade / Freddie Barnfield - Nominated Adviser | www.numiscorp.com | |
James Black - Corporate Broking | ||
Walbrook PR Limited | Tel: +44 (0) 20 7933 8780 or avacta@walbrookpr.com | |
Paul McManus | Mob: +44 (0)7890 541 893 | |
Lianne Cawthorne | Mob: +44 (0)7584 391 303 | |
About Avacta Group plc - www.avacta.com
Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. Avacta operates through two divisions:
Avacta Animal Health www.avactaanimalhealth.com | Veterinary diagnostics reference laboratory and diagnostic kit provider. |
Avacta Life Sciences www.avactalifesciences.com
| Novel non-antibody affinity reagents called Affimers, with a wide range of Life Science applications in diagnostics, drug and biomarker discover and biotech research and development. |
Avacta Group (AVCT)